|1.||Wang, Qi: 4 articles (10/2011 - 07/2007)|
|2.||Mizushina, Yoshiyuki: 3 articles (06/2015 - 11/2012)|
|3.||Kuriyama, Isoko: 3 articles (06/2015 - 11/2012)|
|4.||Kobayashi, Yuko: 3 articles (06/2014 - 01/2012)|
|5.||Jippo, Tomoko: 3 articles (06/2014 - 01/2012)|
|6.||Nakayama, Hiroto: 2 articles (06/2014 - 11/2012)|
|7.||Mitoshi, Mai: 2 articles (06/2014 - 11/2012)|
|8.||Yoshida, Hiromi: 2 articles (06/2014 - 11/2012)|
|9.||Sugimoto, Keiichiro: 2 articles (06/2014 - 11/2012)|
|10.||Miyazato, Hironari: 2 articles (06/2014 - 11/2012)|
01/01/2009 - "These data suggest that A23187 could be an alternative potential therapeutic drug used for anti-proliferation in LKB1-deficient cancer cells."
04/01/1990 - "Macrophages express antitumor cytostatic activity towards P815 cells (49-53%) in a cocultured ratio (macrophage: tumor cell) 2:1 when stimulated with 3.5 x 10(-7) M A23187 in TGM. "
12/01/1988 - "A23187-stimulated cytostatic activity of peritoneal macrophages towards P815 tumor cells served as a model for macrophage activation: a macrophage enriched preparation, separated on the basis of cell size in a discontinuous FCS gradient column, expressed cytostatic activity when stimulated by A23187. "
03/01/1988 - "This symplastic transport was inhibited with Ca2+ in the presence of ionophore A23187, and also with the tumor promoter 12-O-tetradecanoyl-phorbol-13-acetate (TPA). "
08/01/1985 - "The proportions of apparently "bound" and "free" Mg2+ (inferred from release by the ionophore, A23187) do not differ significantly between tumor and liver mitochondria. "
11/01/2002 - "Hypoxia stimulated PAF synthesis via remodeling pathway only in PVSMC (408+/-32 vs 225+/-17) which was 5-fold greater than in PASMC (77+/-15 vs 105+/-24), however, with A23187 in remodeling pathway, PAF synthesis increased 5-fold compared to baseline conditions and then synthesis in hypoxia was greater than in normoxia in both cell types. "
07/01/1999 - "Proximal tubule segments (PTS) from normal CD-1 mice were subjected to either 30 minutes of hypoxia, Ca2+ ionophore (50 microM A23187), or oxidant attack (50 microM Fe). "
01/01/1984 - "[Ca2+]i was raised experimentally in mammalian and amphibian skeletal and cardiac muscles by A23187, DNP, anoxia or the Ca2+ -paradox. "
09/01/1983 - "I. Reversible effects of anoxia, KCN, and influences of the Ca2+ ionophore A-23187."
12/01/1982 - "4. When a low concentration of X537A was applied the shape of the contractile response to A23187 was changed from a sustained development of tension to an oscillatory tension which was also observed under hypoxia. "
|3.||Lung Neoplasms (Lung Cancer)
07/01/2007 - "A23187 treatment is highly effective for the induction of GRP78 and subsequent development of resistance to VP-16 in the human lung cancer NCI-H460 cell line. "
10/01/2011 - "In this study, we investigated the up-regulation of GRP78 induced by A23187 and its association with the chemotherapeutical sensibility to cisplatin in human lung cancer cell line SPCA1. "
10/01/2011 - "To a certain extent, GRP78 up-regulation by A23187 was associated with the enhancement of drug sensitivity to cisplatin in human lung cancer cell line SPCA1."
12/01/2003 - "Moreover, both plasma and bronchoalveolar lavage fluid obtained from treated subjects significantly reduced the production of PGE2 that resulted when a lung cancer cell line, A549, was stimulated with IL-1beta or A23187. "
01/01/2010 - "The aim of this study was to investigate the expression of GRP78 under the induction of A23187 and its significance in the resistance to anti-tumor drugs cisplatin in a human lung cancer SPCA-1 cell line. "
05/01/1989 - "The compound inhibited leukotriene biosynthesis in vivo in a rat pleurisy model (ED50, 0.2 mg/kg p.o.), an inflamed rat paw model (ED50, 0.8 mg/kg), a model of leukotriene excretion in rat bile following antigen provocation, and a model in the guinea-pig ear where leukotriene synthesis was induced by topical challenge with ionophore A23187 (ED50, 2.5 mg/kg p.o. "
07/01/1988 - "We also studied the involvement of endogenous prostaglandins (PGs) in the cytoprotective action of roxatidine and the effect of roxatidine on SRS content in pleurisy induced by A23187. "
01/01/1992 - "MK-886 was effective in Ascaris-induced asthma in squirrel monkeys, in rat carrageenan pleurisy, in rat Arthus pleurisy, and (topically) in guinea-pig ear oedema induced by A23187.(ABSTRACT TRUNCATED AT 400 WORDS)"
04/01/1997 - "The carrageenan-induced pleurisy model modifid by A23187 administration was used to study the oral effect of CGS 23885 (N-hydroxy-N-[(6-phenoxy-2H-1-benzopyran-3-yl)-methyl]urea), a potent 5-lipoxygenase (5-LO) inhibitor, on inflammatory parameters. "
10/01/1990 - "Pleural and peritoneal cells were collected at various times after pleurisy induction and tested for production of leukotriene B4 (LTB4), prostaglandin E2 (PGE2) and prostacyclin (PGI2) after in-vitro stimulation with calcium ionophore A23187. "
|5.||Asthma (Bronchial Asthma)
10/01/2007 - "Severe asthma patients in both AERD [0.5 (0.8)] ng/mL and ATA [0.5 (0.45) ng/mL] groups showed diminished generation for LX A4 to stimulation with A23187 in comparison with other severity degrees in their groups (P=0.02 and 0.046, respectively). "
07/01/2000 - "To investigate the cellular sources of arachidonate metabolites during asthma, in vitro productions of thromboxane (TX) B2, prostaglandin (PG) D2, leukotriene (LT) B4 and cysteinyl (Cys) LTs from guinea pig eosinophils and macrophages simultaneously stimulated with the Ca ionophore A23187 were investigated. "
11/01/1996 - "The change in Km following stimulation with A23187 was also significantly less during acute asthma than previously measured in nonasthmatic subjects (p=0.003). "
11/01/1995 - "In contrast, potentiation was not seen with PHA or A23187 in the total group of patients with asthma. "
10/01/1993 - "The histamine release induced by Ca ionophore A23187 from cells in the bronchoalveolar lavage (BAL) fluid of atopic asthmatics was significantly lower in the subgroup with steroid-dependent intractable asthma (SDIA) than in non-SDIA patients (p < 0.05). "
|5.||Etoposide (VP 16)
|6.||Egtazic Acid (EGTA)
|7.||Epidermal Growth Factor (EGF)
|8.||Nerve Growth Factor (NGF)
|10.||Arachidonic Acid (Vitamin F)